Sirtris Pharmaceuticals Presents at the American Diabetes Association's 68th Annual Scientific Sessions June 8
June 04 2008 - 7:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced that
it will be presenting at the American Diabetes Association�s 68th
Annual Scientific Sessions in San Francisco. Peter Elliott, PhD,
Senior Vice President of Development at Sirtris, will speak at the
symposium titled Speed and Endurance, Nature or Nurture? His talk
is on Sunday, June 8 beginning at 3:30 pm. Sirtris will also give
two poster presentations: Activation of the Protein Deacetylase
SIRT1 Blunts Pro-Inflammatory Pathways in vivo; and Novel Small
Molecule Activators of SIRT1 as a Therapeutic Approach to Type 2
Diabetes: The Identification of SRT100 as a Clinical Candidate.
Both poster presentations will be on Sunday, June 8 beginning at
noon. Sirtris has announced positive Phase 1b clinical trial
results with drug candidate SRT501, a proprietary formulation of
resveratrol, in patients with Type 2 Diabetes. Sirtris has also
developed new chemical entities (NCEs) that are chemically distinct
from and more potent, in vitro, than resveratrol. The NCEs have
been shown to lower glucose and improve insulin sensitivity in
pre-clinical models of Type 2 Diabetes. These SIRT1 activators have
the potential to be a frontline therapy for Type 2 Diabetes. About
Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a
biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
the Company believes control the aging process. Sirtris
Pharmaceuticals is engaged in human clinical trials for Type 2
Diabetes, and is planning similar trials in cancer, another
age-related disease. Sirtris is also engaged in a human clinical
trial for MELAS, a mitochondrial disorder. The company�s
headquarters are in Cambridge, Massachusetts. On June�2,
2008,�GlaxoSmithKline plc announced the successful completion by an
indirect wholly-owned subsidiary�of�a tender offer to purchase�all
of the�outstanding shares of Sirtris common stock. Approximately
97% of�Sirtris's outstanding shares�were tendered in the offer.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements include, but are not limited to, the potential
therapeutic effects of SIRT1 activators including NCEs for diseases
of aging, such as Type 2 Diabetes; the success of SIRT1 activators
as therapies for diseases, such as Type 2 Diabetes; the progress
and results of preclinical and clinical studies of SIRT1
activators, such as SRT501 and Sirtris� NCEs; and the potential of
sirtuin modulators to receive regulatory approval. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company�s product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company�s potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company�s product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company�s product
candidates, and those other risks factors that can be found in the
Company�s filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Apr 2024 to May 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From May 2023 to May 2024